Compare Robinhood Markets, Inc. (HOOD) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Robinhood Markets, Inc. vs IDEXX Laboratories, Inc. — how do they compare? Robinhood Markets, Inc. trades at $94.7 (market cap $84.86B), while IDEXX Laboratories, Inc. trades at $569.65 (market cap $46.22B). The key difference: Robinhood Markets, Inc. is the larger of the two by market cap, and Robinhood Markets, Inc. is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals.
| HOOD | IDXX | |
|---|---|---|
Market Cap | $84.86B | $46.22B |
Sector | Technology | Health |
52-Week High | $152.46 | $766.68 |
52-Week Low | $65.16 | $526.44 |
Enterprise Value | $91.40B | $47.12B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Robinhood Markets (HOOD) trades at $95.19, up 0.71% on the day, with the stock showing strong fundamental momentum despite a bearish technical signal. The company reported impressive 2025 results with $4.47B revenue and $1.88B net income, representing 42% net margins. Recent Q2 2026 earnings beat expectations with $0.62 EPS versus $0.44 expected, though technical indicators show resistance near $95-97 levels with RSI suggesting potential overbought conditions.
HOOD presents a compelling growth story with 73% analyst buy ratings and a $123.46 consensus price target representing 30% upside potential. Key opportunities include international expansion and product diversification beyond crypto, while risks involve competitive pressures and market volatility sensitivity. The company's transition to profitability and strong cash flow generation support long-term bullish thesis despite near-term technical headwinds.
IDEXX Laboratories (IDXX) trades at $571.44, down 4.08% over the past day, amid a mixed technical and strong fundamental backdrop. The stock shows a bullish trend in moving averages but overbought RSI readings near 73. Recent Q2 2026 earnings beat expectations with 9% organic revenue growth, and the company raised full-year EPS guidance. Profitability remains robust with a 25.03% net income margin and 74.21% ROE.
The outlook is positive given strong earnings momentum, high analyst buy ratings, and a consensus price target of $683.33 implying ~20% upside. Risks include premium valuation multiples and potential market volatility. The stock presents a growth opportunity supported by durable competitive advantages in veterinary diagnostics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Robinhood Markets, Inc.
Robinhood Markets, Inc. operates a financial services platform. The Company offers brokerage and cash management applications such as stocks, exchange-traded funds, options, and cryptocurrency. Robinhood Markets serves clients in the United States.
Read more on HOOD →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
